Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash from Operations (2021 - 2025)

Historic Cash from Operations for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to -$30.4 million.

  • Amylyx Pharmaceuticals' Cash from Operations rose 2694.73% to -$30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.4 million, marking a year-over-year decrease of 6242.64%. This contributed to the annual value of -$167.6 million for FY2024, which is 150655.26% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Cash from Operations of -$30.4 million as of Q3 2025, which was up 2694.73% from -$25.2 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' Cash from Operations' 5-year high stood at $13.6 million during Q4 2023, with a 5-year trough of -$66.6 million in Q2 2024.
  • Its 5-year average for Cash from Operations is -$26.6 million, with a median of -$28.2 million in 2021.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Cash from Operations surged by 12726.72% in 2023, and later plummeted by 804396.73% in 2025.
  • Amylyx Pharmaceuticals' Cash from Operations (Quarter) stood at -$28.2 million in 2021, then plummeted by 75.96% to -$49.7 million in 2022, then soared by 127.27% to $13.6 million in 2023, then plummeted by 535.45% to -$59.0 million in 2024, then skyrocketed by 48.54% to -$30.4 million in 2025.
  • Its Cash from Operations stands at -$30.4 million for Q3 2025, versus -$25.2 million for Q2 2025 and -$39.8 million for Q1 2025.